Australia-based Endo Axiom Pty Ltd has dosed its first human participants with an oral nanoparticle-encapsulated insulin formulation, marking the company's... London-based neurotechnology company ...
Endo Axiom begins first human dosing of oral insulin nanoparticles for type 1 diabetes. Phase Ia trial shows breakthrough in ...
Teva Pharmaceutical refinances $4.9B debt, retiring high-coupon notes up to 8.125%. Learn how the pharma giant extends its maturity profile and ...
IMUNON partners with National Cancer Institute to advance IMNN-001 IL-12 immunotherapy beyond ovarian cancer. NCI assumes ...
Exegenesis Bio and Japan-based Modalis Therapeutics Corporation (Tokyo: 4883) signed a research collaboration and license agreement to advance MDL-201, a preclinical epigenome editing candidate for ...
Yarrow Bioscience secures $150M funding to advance first-in-class Graves' disease antibody into Phase II trials. Latest ...
NeuroHarmonics begins first patient trial of non-invasive deep-brain ultrasound for essential tremor. MHRA cleared. Learn ...
Gan & Lee Pharmaceuticals begins Phase I testing of GZC8072, a once-weekly oral GLP-1 peptide for type 2 diabetes and weight management. Learn more.
Johns Hopkins receives $2.5 million NIH grant to study TLR4's role in necrotizing enterocolitis. Discover breakthrough ...
FDA pushes zanzalintinib decision to March 2027. Exelixis' colorectal cancer drug review extended by 3 months. Latest updates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results